TY  - JOUR
TI  - Personalized microbiome biotherapeutics across recurrent CDI, cancer immunotherapy, ulcerative colitis and MDRO decolonization: a PRISMA 2020 systematic review with structured narrative synthesis
AU  - M.E. Shoranov
AU  - Sh.B. Tanabaeva
AU  - Z.S. Kachieva
AU  - A.M. Tlenchieva
AU  - A.Zh. Kauysbekov
AU  - Zh.S. Alibaeva
JO  - Global Medical Reviews
PY  - 2026
DA  - 2026-07-27
VL  - 1
IS  - 1
SP  - e0001
KW  - personalized microbiome medicine
KW  - microbiome biotherapeutics
KW  - fecal microbiota transplantation
KW  - donor-recipient matching
KW  - metagenomics
KW  - metabolomics
KW  - immunotherapy
KW  - Clostridioides difficile
AB  - Background: Microbiome biotherapeutics range from standardized indication-specific products to donor-, recipient- and ecology-informed interventions. Objective: To evaluate the clinical efficacy, safety, and reproducibility of microbiome biotherapeutics and determine how donor, product, recipient, and longitudinal multi-omics characteristics have been used to personalize treatment. Methods: PubMed/MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov were searched from inception to 8 July 2026, supplemented by regulatory sources, publisher searches, and citation tracking. Results: Twenty-seven unique studies represented by 28 eligible reports were included across recurrent CDI, oncology and immunotherapy, ulcerative colitis, and MDRO decolonization. Conclusions: Current routine evidence is strongest for standardized microbiota-based prevention of recurrent CDI after antibacterial therapy. Validated patient-level personalization is not yet established.
UR  - https://glr.sciences.kz/article/personalized-microbiome-biotherapeutics
L2  - https://glr.sciences.kz/downloads/GMR_2026_1_1_e0001_personalized-microbiome-biotherapeutics.pdf
ER  -